Publications
Detailed Information
The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Chul-Hee | - |
dc.contributor.author | Lim, Ilhan | - |
dc.contributor.author | Woo, Sang-Keun | - |
dc.contributor.author | Kim, Kwang Il | - |
dc.contributor.author | Lee, Kyo Chul | - |
dc.contributor.author | Song, Kanghyon | - |
dc.contributor.author | Choi, Chang Woon | - |
dc.contributor.author | Lim, Sang Moo | - |
dc.date.accessioned | 2022-10-17T04:17:27Z | - |
dc.date.available | 2022-10-17T04:17:27Z | - |
dc.date.created | 2022-10-12 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.citation | Cancer Biotherapy and Radiopharmaceuticals, Vol.37 No.6, pp.417-423 | - |
dc.identifier.issn | 1084-9785 | - |
dc.identifier.uri | https://hdl.handle.net/10371/186197 | - |
dc.description.abstract | Copyright © 2022, Mary Ann Liebert, Inc.Background: The goal of this research was to investigate the feasibility of 64Cu labeling in prostate-specific membrane antigen imaging and therapy (PSMA I&T) for PSMA positron emission tomography (PET) imaging and biodistribution evaluation. Materials and Methods: PSMA I&T was labeled with 64Cu, and stability in human and mouse sera was evaluated. Prostate cancer cell lines were used for specific uptake assays (22RV1 for PSMA-positive, PC-3 for -negative). Both PC-3 and 22RV1 cells were transplanted into the left and right thighs in a mouse for PET/computed tomography (CT) imaging. Biodistribution was performed using 22RV1 tumor models. Results: Labeling yield (decay corrected) of 64Cu-PSMA I&T was more than 95% compared to the free 64Cu peak. The serum stability of 64Cu-PSMA I&T was maintained at more than 90% until 60 h. Regarding the specific binding of 64Cu-PSMA I&T was 7.5-fold higher to 22RV1 cells than PC-3 cells (p < 0.001). On PET/CT imaging, more specific 64Cu-PSMA I&T uptake was observed to 22RV1 tumors than to PC-3 tumors. In the PSMA blocking study using 2-phosphonomethoxypropyl adenine (2-PMPA), the 64Cu-PSMA I&T signal significantly decreased in the 22RV1 tumor region. In the biodistribution study, the kidney uptake was the highest among all organs at 2 h (52.6 ± 20.8%ID/g) but sharply decreased at 24 and 48 h. Also, the liver showed similar uptake over time (range, 10-12%ID/g). On the contrary, 64Cu-PSMA I&T uptake of the tumors increased with time and peaked at 48 h (5.6 ± 0.1%ID/g). Conclusions: PSMA I&T labeled with 64Cu showed the feasibility of the PSMA specific PET imaging through in vitro and in vivo studies. Furthermore, 64Cu-PSMA I&T might be considered as the candidate of future clinical trial. | - |
dc.language | 영어 | - |
dc.publisher | Mary Ann Liebert Inc. | - |
dc.title | The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1089/cbr.2020.4189 | - |
dc.citation.journaltitle | Cancer Biotherapy and Radiopharmaceuticals | - |
dc.identifier.scopusid | 2-s2.0-85135597519 | - |
dc.citation.endpage | 423 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 417 | - |
dc.citation.volume | 37 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Kwang Il | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.